natgillin/translations-raw huggingface dataset:
Almindelige bivirkninger Det er almindeligt, at de følgende bivirkninger forekommer, men de fleste af dem er milde og kan afhjælpes (forekommer hos mere end 1 af 100, men mindre end 1 af 10 patienter). o Hårtab o Acne o Migræne o Søvnløshed/ dårlig søvnkvalitet o Dybere stemme eller hæshed o Brystsmerter o Vægtforøgelse o Mavesmerter
Common side effects The following side effects may occur commonly (in more than 1 out of 100, but less than 1 out of 10 patients), but most of them are mild in nature and reversible. o hair loss o acne o migraine o insomnia/ inability to sleep properly o voice deepening or hoarseness o breast pain o weight gain o abdominal pain
Hvis en bivirkning bliver alvorlig, eller De bemærker en hvilken som helst af de bivirkninger, som er nævnt ovenfor, eller bivirkninger, som ikke er nævnt i denne indlægsseddel, bør De fortælle det til Deres læge.
If any of the side effects become serious, or if you notice any side effects mentioned above or side effects not listed in this leaflet, please tell your doctor.
HVORDAN DE OPBEVARER INTRINSA
HOW TO STORE INTRINSA
 Opbevares utilgængeligt for børn.  Må ikke opbevares over 30 oC.  Må ikke opbevares i køleskab eller nedfryses.
 Keep out of the reach and sight of children.  Do not store above 30°C.  Do not refrigerate or freeze.
23 Anvend ikke Intrinsa efter udløbsdatoen, som er angivet på æsken og brevet.
23 Do not use Intrinsa after the expiry date which is stated on the carton and sachet.
Hvad Intrinsa indeholder Det aktive stof er testosteron.
What Intrinsa contains The active substance is testosterone.
Hvert plaster indeholder 8, 4 mg testosteron og afgiver 300 mikrogram testosteron på 24 timer.
Each patch contains 8.4 mg of testosterone, releasing 300 micrograms of testosterone over 24 hours.
Sorbitanoleat, 2- etylhexyl- akrylat – 1- vinyl- 2- pyrrolidon copolymer.
Sorbitan oleate, 2-Ethylhexylacrylate – 1-Vinyl-2-pyrrolidone co-polymer.
Intrinsas udseende og pakningsstørrelse Intrinsa er et tyndt, klart, ovalt plaster med PG T001 trykt på bagsiden.
What Intrinsa looks like and contents of the pack Intrinsa is a thin, clear, oval patch with PG T001 stamped on the back.
Det fås i følgende pakningsstørrelser:
The following pack sizes are available:
2, 8 og 24 plastre.
2, 8 and 24 patches.
Indehaveren af markedsføringstilladelsen Procter & Gamble Pharmaceuticals UK Ltd.
Marketing Authorisation Holder Procter & Gamble Pharmaceuticals UK Ltd.
Rusham Park Technical Centre Whitehall Lane Egham, Surrey TW20 9NW Storbritannien
Rusham Park Technical Centre Whitehall Lane Egham, Surrey TW20 9NW United Kingdom
Fremstiller Procter & Gamble Pharmaceuticals – Germany GmbH Dr. - Otto- Röhm- Strasse 2- 4 D- 64331 Weiterstadt Tyskland
Manufacturer Procter & Gamble Pharmaceuticals – Germany GmbH Dr. -Otto-Röhm-Strasse 2-4 D-64331 Weiterstadt Germany
Yderligere information om dette lægemiddel er tilgængeligt på Det Europæiske Lægemiddelag enturs (EMEAs) hjemmeside: http: // www. emea. europa. eu /
Detailed information on this medicine is available on the European Medicines Agency (EMEA) web site: http: / /www. emea. europa. eu
IntronA er et lægemiddel, der indeholder det aktive stof interferon alfa- 2b.
IntronA is a medicine containing the active substance interferon alfa-2b.
Det leveres som pulver og solvens, der skal blandes til en injektionsvæske eller infusionsvæske, opløsning, som en brugsklar injektionsvæske, opløsning, og som en multidosis injektionspen.
It is available as a powder and solvent to be made into a solution for injection or infusion, as a ready-to-use solution for injection and as a multidose pen for injection.
IE (internationale enheder) pr. milliliter.
These contain from 1 to 50 million IU (international units) per millilitre.
IntronA anvendes til behandling af: • kronisk (langvarig) hepatitis B (en leversygdom, der skyldes en infektion med hepatitis B - virus) hos voksne, • kronisk hepatitis C (en leversygdom, der skyldes en infektion med hepatitis C- virus).
IntronA is used for the treatment of: • chronic (long-term) hepatitis B (a disease of the liver due to an infection by the hepatitis B virus) in adults, • chronic hepatitis C (a disease of the liver due to an infection by the hepatitis C virus).
Hos voksne kan IntronA anvendes alene, men det er bedst at anvende det i kombination med ribavirin (et antiviralt lægemiddel), og hos børn anvendes det sammen med ribavirin, • hårcelleleukæmi (kræft i de hvide blodlegemer), • kronisk myeloid leukæmi (CML) (en anden kræftform, der rammer de hvide blodlegemer) hos voksne.
In adults IntronA can be used on its own but is best used in combination with ribavirin (an antiviral medicine), and in children, it is used with ribavirin, • hairy cell leukaemia (a cancer of the white blood cells), • chronic myelogenous leukaemia (CML, another cancer of the white blood cells) in adults.
IntronA kan anvendes i kombination med cytarabin (et lægemiddel mod kræft) i de første 12 måneder, • multipel myelom (knoglemarvskræft).
IntronA can be used in combination with cytarabine (an anticancer medicine) in the first 12 months, • multiple myeloma (a cancer of the bone marrow).
IntronA anvendes til at opretholde de kræfthæmmende virkninger hos patienter, der har reageret positivt på tidligere behandling med lægemidler mod kræft, • follikulær lymfom (kræft i lymfevævet).
IntronA is used to maintain anticancer effects in patients who have responded to a previous treatment with anticancer medicines, • follicular lymphoma (a cancer of the lymph tissue).
IntronA anvendes som supplerende behandling til kræftbehandlinger, • karcinoid tumor (en tumor i det endokrine system, der producerer hormoner), • malignt melanom (modermærkekræft – en type hudkræft, der påvirker de celler, der kaldes melanocytter (pigmentceller)).
IntronA is used as an add-on to anticancer treatments, • carcinoid tumour (a tumour of the endocrine system that produces hormones), • malignant melanoma (a type of skin cancer affecting cells called melanocytes).
Behandlingen med IntronA bør varetages af en læge med erfaring i behandling af den sygdom, lægemidlet anvendes til.
Treatment with IntronA should be initiated by a doctor who has experience in the management of the disease it is being used for.
IntronA gives normalt tre gange om ugen (hver anden dag), men injektionen 7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
7 Westferry Circus, Canary Wharf, London E14 4HB, UK Tel.
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged kan gives hyppigere i forbindelse med visse sygdomme (kronisk myeloid leukæmi og melanom).
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged the response of the patient, with doses ranging from 2 to 20 million IU per square metre of body surface area.
IntronA skal opbevares i køleskab (2°C - 8°C).
IntronA has to be stored in a refrigerator (2°C-8°C).
Det aktive stof i IntronA, interferon alfa- 2b, hører til gruppen af ‘ interferoner ’.
The active substance in IntronA, interferon alfa-2b, belongs to the group ‘ interferons’.
Den nøjagtige måde, hvorpå alfa- interferoner virker mod kræft - og virussygdomme kendes endnu ikke fuldt ud, men man mener, at de virker som immunmodulatorer (stoffer der ændrer den måde, hvorpå immunsystemet (kroppens forsvarssystem) fungerer).
The exact way alpha interferons work in cancer and viral diseases in not fully understood, but it is thought that they act as immunomodulators (substances that modify how the immune system, the body ’ s defence system, works).
Alfa - interferoner kan ligeledes blokere formeringen af vira.
Alpha interferons may also block the multiplication of viruses.
Interferon alfa- 2b i IntronA produceres ved en metode, der kaldes ‘ rekombinant DNA- teknologi ’: interferon alfa- 2b produceres af en bakterie, der har modtaget et gen (DNA), som sætter bakterien i stand til at producere stoffet.
The interferon alfa-2b in IntronA is produced by a method known as ‘ recombinant DNA technology’: the interferon alfa-2b is made by a bacterium that has received a gene (DNA), which makes it able to produce it.
Erstatningsinterferon alfa- 2b virker på samme måde som naturligt produceret interferon alfa.
The replacement interferon alfa-2b acts in same way as naturally produced interferon alpha.
Da interferon alfa- 2b tidligere er blevet anvendt til behandling af en række sygdomme i EU, har firmaet, der fremstiller IntronA, fremlagt data fra den videnskabelige litteratur og fra undersøgelser af brugen af interferon alfa- 2b sammen med cytarabin hos 745 patienter med kronisk myeloid leukæmi, samt data fra brugen af interferon alfa- 2b til børn med kronisk hepatitis B.
Because interferon alfa-2b has been used to treat a number of diseases in the European Union (EU) before, the company that makes IntronA supplied data from the scientific literature and from studies of its use with cytarabine in CML (745 patients) and of its use in children with chronic hepatitis B.
Ansøgeren fremlagde ligeledes resultater fra en række undersøgelser, hvor IntronA blev anvendt alene eller sammen med ribavirin til behandling af kronisk hepatitis C.
The company also supplied information from a number of studies of IntronA used alone or with ribavirin for the treatment of chronic hepatitis C.
Disse undersøgelser omfattede i alt 2 552 behandlingsnaive patienter (som ikke var blevet behandlet tidligere) og i alt 345 patienter, hvis sygdom var vendt tilbage efter tidligere behandling med interferon.
These included a total of 2,552 treatment-naïve patients (who had not been treated before) and a total of 345 patients whose disease had relapsed (returned) after previous treatment with interferon.
Brugen af IntronA i kombination med ribavirin er endvidere blevet undersøgt hos 118 behandlingsnaive børn med hepatitis C i alderen 3– 16 år.
The use of IntronA in combination with ribavirin has also been studied in 118 hepatitis C treatment-naïve children aged between 3 and 16 years.
Virkningen blev hovedsagelig bedømt på responsraten (hvor mange patienter der reagerede positivt på behandlingen) i undersøgelserne med hepatitispatienter, og på overlevelsestiden i undersøgelserne med kræftpatienter.
The main measures of effectiveness were response rates in the hepatitis studies and survival time in the cancer studies.
Undersøgelserne viste, at IntronA er effektivt til behandling af de sygdomme, til hvilke det er indikeret.
The studies showed that IntronA is effective in the diseases for which it can be used.
Blandt patienterne med kronisk myeloid leukæmi var flere i live efter 3 år i den gruppe, som fik IntronA sammen med cytarabin, end i gruppen behandlet med IntronA alene.
In CML, more patients who received IntronA with cytarabine were still alive after 3 years than patients who only received IntronA.
IntronA har også vist sig at være fordelagtig til børn med kronisk hepatitis B.
IntronA was also shown to have a benefit in children with chronic hepatitis B.
IntronA, sammen med eller uden ribavirin, viste sig at være effektiv til behandling af hepatitis C hos både behandlingsnaive voksne og hos voksne, hvis sygdom var vendt tilbage.
IntronA, with or without ribavirin, was shown to be effective in treating hepatitis C in both treatment- naïve and relapsed adults.
Det var ligeledes effektivt til børn, når det blev anvendt sammen med ribavirin, idet 46% af børnene havde reageret positivt på behandlingen ved det 6 - måneders kontrolbesøg, der fulgte efter 1 års behandling.
It was also effective in children, when used with ribavirin, with 46% of the children having responded to treatment at the 6-month follow up visit following 1-year treatment.
De hyppigste bivirkninger i forbindelse med IntronA (generelt indberettet hos flere end 1 ud af 10 patienter) er virusinfektioner, ondt i halsen (pharyngitis), appetitløshed, depression, søvnløshed, angst, humørsvingninger, hovedpine, nedsat koncentrationsevne, svimmelhed, hoste, åndenød (dyspnø), kvalme, diarré, mavesmerter, hårtab, kløe (pruritus), tør hud, udslæt, muskelsmerter, ledsmerter, muskel - og knoglesmerter, reaktioner på injektionsstedet (herunder betændelse), træthed, kulderystelser, feber, influenzalignende symptomer, svækkelse (asteni), irritabilitet og vægttab.
The most common side effects with IntronA (generally reported in more than 1 patient in 10) are viral infections, pharyngitis (sore throat), anorexia (loss of appetite), depression, insomnia (difficulty sleeping), anxiety, emotional lability (mood swings), headache, impaired concentration, dizziness, cough, dyspnoea (difficulty breathing), nausea (feeling sick), diarrhoea, abdominal (tummy) pain, alopecia (hair loss), pruritus (itching), dry skin, rash, myalgia (muscle pain), arthralgia (joint pain), musculoskeletal pain (pain in the muscles and bones), reactions at the site of the injection including inflammation, fatigue (tiredness), rigors (shaking chills), fever, flu-like symptoms, asthenia (weakness), irritability and weight loss.
Den fuldstændige liste over de indberettede bivirkninger ved IntronA fremgår af indlægssedlen.
For the full list of all side effects reported with IntronA, see the Package Leaflet.
IntronA bør ikke anvendes af personer, som kan være overfølsomme (allergiske) over for interferon alfa- 2b eller et af de øvrige indholdsstoffer.
IntronA should not be used in people who may be hypersensitive (allergic) to interferon alfa-2b or any of the other ingredients.
IntronA bør ikke anvendes af: • Patienter med alvorlig hjertesygdom, • Patienter med alvorlig nyre - eller leversygdom, herunder en sådan, der er forårsaget af kræft,
IntronA should not be used in: • patients with severe heart disease, • patients with severe kidney or liver disease including that caused by cancer, • patients with epilepsy or other central nervous system problems, • patients with thyroid disease unless it is controlled, • hepatitis patients with liver cirrhosis or who have recently received medicines that affect the immune system, • patients with a history of certain disorders of the immune system, or have had an organ transplant and are taking medicine that suppress immune system • children and adolescents with a history of severe mental illness, particularly severe depression, suicidal thoughts or suicide attempts.
Den fuldstændige liste over begrænsninger i forbindelse med IntronA fremgår af indlægssedlen.
For a list of all restrictions with IntronA, see the Package Leaflet.
Udvalget for Humanmedicinske Lægemidler (CHMP) var af den opfattelse, at fordelene ved IntronA opvejer risiciene ved behandling af kronisk hepatitis B og C, hårcelleleukæmi, kronisk myeloid leukæmi, multipel myelom, follikulær lymfom, karcinoid tumor og modermærkekræft.
The Committee for Medicinal products for Human Use (CHMP) decided that IntronA’ s benefits are greater than its risks for the treatment of chronic hepatitis B and C, hairy cell leukaemia, CML, multiple myeloma, follicular lymphoma, carcinoid tumour and malignant melanoma.
Udvalget anbefalede udstedelse af markedsføringstilladelse for IntronA.
The Committee recommended that IntronA be given marketing authorisation.
Andre oplysninger om IntronA:
Other information about IntronA:
Europa- Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for IntronA til SP Europe den 9. marts 2000.
The European Commission granted a marketing authorisation valid throughout the European Union, for IntronA to SP Europe on 9 March 2000.
Den fuldstændige EPAR for IntronA findes her.
The full EPAR for IntronA is available here.
Handelsn Styrke avn
Invented Name
Indhold (Koncentration)
Content (Concentration)
1 million IE
1 million IU/ ml
Pulver og solvens til Injektionsvæske, opløsning
Powder and solvent for solution for injection or infusion
subkutan eller intravenøs anvendelse
Subcutaneous or intravenous use
Hætteglas / Solvens:
Powder: vial (glass) Solvent: ampoule (glass)
Ampul 1, 0 ml (1 million IE/ ml) (glas)
1.0 ml (1 million IU/ ml)
1 hætteglas + 1 ampul + 1 injektionssæt1
1 vial + 1 ampoule + 1 injection set1
3 millioner IE
3 million IU/ ml
Pulver og solvens til injektionsvæske, opløsning
Powder and solvent for solution for injection or infusion
Ampul 1, 0 ml (3 millioner IE/ ml) (glas)
1.0 ml (3 million IU/ ml)
5 millioner IE
5 million IU/ ml
Ampul 1, 0 ml (5 millioner IE/ ml) (glas)
1.0 ml (5 million IU/ ml)
6 hætteglas +6 ampuller
6 vials + 6 ampoules
10 millioner IE
10 million IU/ ml
Ampul 1, 0 ml (10 millioner IE/ ml) (glas)
1.0 ml (10 million IU/ ml)
1 hætteglas +1 ampul + 1 injektionssæt
1 vial + 1 ampoule + 1 injection set1
10 hætteglas +10 ampuller +10 injektionssæt1
10 vials + 10 ampoules + 10 injection sets1
EU/ 1/ 99/ 127/ 009 IntronA
EU/ 1/ 99/ 127/ 009
18 millioner IE
18 million IU/ ml
Ampul 1, 0 ml (18 millioner IE/ ml) (glas)
1.0 ml (18 million IU/ ml)
30 millioner IE
30 million IU/ ml
Ampul 1, 0 ml (30 millioner IE/ ml) (glas)
1.0 ml (30 million IU/ ml)
3 millioner IE
3 million IU/ 0.5ml
Injektionsvæske, opløsning
Solution for injection or infusion
0. 5 ml (6 millioner IE/ ml)
0.5 ml (6 million IU/ ml)
12 hætteglas +12 injektionssæt2
12 vials + 12 injection sets2
5 millioner IE
5 million IU/ 0.5ml
0, 5 ml (10 millioner IE/ ml)
0.5 ml (10 million IU/ ml)
EU/ 1/ 99/ 127/ 019 IntronA
EU/ 1/ 99/ 127/ 019
1, 0 ml (10 millioner IE/ ml)
1.0 ml (10 million IU/ ml)
subkutan eller intravenøs anv.
Subcutaneous or intravenous use
18 millioner IE
18 million IU/ 3ml
3, 0 ml (6 millioner IE/ ml)
3.0 ml (6 million IU/ ml)
1 hætteglas + 6 injektionssæt2
1 vial + 6 injection sets4
EU nummer
2 vials
25 millioner IE
25 million IU/ 2.5ml
2, 5 ml (10 millioner IE/ ml)
2.5 ml (10 million IU/ ml)
EU/ 1/ 99/ 127/ 029 IntronA
EU/ 1/ 99/ 127/ 029
18 millioner IE
18 million IU
Injektionsvæske, opløsning i flerdosispen
Solution for injection in a multidose pen
subkutan anvendelse
Subcutaneous use
Cylinderampul (glas) i flerdosispen
Cartridge (glass) in multidose pen
1, 2 ml (15 millioner IE/ ml)
1.2 ml (15 million IU/ ml)
1 pen + 6 injektionssæt3
1 pen + 12 injection sets3
2 penne + 12 injektionssæt3
2 pens + 24 injection sets3
8 penne + 48 injektionssæt3
8 pens + 96 injection sets3
30 millioner IE
30 million IU
1, 2 ml (25 millioner IE/ ml)
1.2 ml (25 million IU/ ml)
1 pen + 6 injektionssæt3
1 pen +12 injection sets3
60 millioner IE
60 million IU
1, 2 ml (50 millioner IE/ ml)
1.2 ml (50 million IU/ ml)
8 penne +48 injektionssæt3
8 pens + 96 injection sets3
/ 1/ 99/ 127/ 040 IntronA
EU/ 1/ 99/ 127/ 040
Ampul (glas)
Powder: vial (glass) Solvent: ampoule (glass)
/ 1, 0 ml (1 million IE/ ml)
1.0 ml (1 million IU/ ml)
12 hætteglas + 12 ampuller + 12 injektionssæt4
12 vials + 12 ampoules + 12 injection sets1
2 hætteglas +5 12 injektionssæt
2 vials + 12 injection sets4
12 hætteglas + 72 injektionssæt5
12 vials + 72 injection sets4
EU/ 1/ 99/ 127/ 044 IntronA 5
EU/ 1/ 99/ 127/ 044
Injektionssæt = injektionssprøjte + kanyle + 2 renseservietter.
1 injection set = injection syringe + 2 injection needles + cleansing swab 2 injection set = injection syringe + injection needle + cleansing swab 3 injection set = injection needle + cleansing swab 4 injection set = injection syringe + injection needle + 2 cleansing swabs
IntronA 1 million IE/ ml pulver og solvens til injektionsvæske eller til infusionsvæske, opløsning
IntronA 1 million IU/ ml powder and solvent for solution for injection or infusion
Et hætteglas med pulver indeholder 1 Million IE interferon alfa- 2b produceret i E. coli ved rekombinant DNA- teknologi.
One vial of powder contains 1 million IU of interferon alfa-2b produced in E. coli by recombinant DNA technology.
Efter rekonstitution, indeholder 1 ml 1 million IE interferon alfa- 2b.
After reconstitution, 1 ml contains 1 million IU of interferon alfa-2b.
Pulver og solvens til injektionsvæske eller til infusionsvæske, opløsning.
Powder and solvent for solution for injection or infusion
Hvidt til cremefarvet pulver.
White to cream coloured powder.
Kronisk hepatitis B:
Chronic Hepatitis B:
Behandling af voksne patienter med kronisk hepatitis B forbundet med tegn på hepatitis B virusreplikation (tilstedeværelse af HBV- DNA og HBeAg), forhøjet alaninaminotransferase (ALAT) og histologisk påvist aktiv leverinflammation og/ eller fibrose.
Treatment of adult patients with chronic hepatitis B associated with evidence of hepatitis B viral replication (presence of HBV-DNA and HBeAg), elevated alanine aminotransferase (ALT) and histologically proven active liver inflammation and/ or fibrosis.
4. 4).
IntronA is indicated for the treatment of adult patients with chronic hepatitis C who have elevated transaminases without liver decompensation and who are positive for serum HCV-RNA or anti-HCV (see section 4.4).
IntronA er beregnet til anvendelse, i kombination med ribavirin, til behandling af børn og unge i alderen 3 år eller ældre, som lider af tidligere ubehandlet kronisk hepatitis C uden leverdekompensation, og som er positive med hensyn til serum HCV- RNA.
IntronA is intended for use, in a combination regimen with ribavirin, for the treatment of children and adolescents 3 years of age and older, who have chronic hepatitis C, not previously treated, without liver decompensation, and who are positive for serum HCV-RNA.
4. 4, 4. 8 og 5. 1).
The expected benefit of treatment should be weighed against the safety findings observed for paediatric subjects in the clinical trials (see sections 4.4, 4.8 and 5.1).
Hårcelleleukæmi:
Hairy Cell Leukaemia:
Kronisk myeloid leukæmi:
Chronic Myelogenous Leukaemia:
Behandling af voksne patienter med Philadelphia kromosom eller bcr/ abl translokationspositiv kronisk myeloid leukæmi.
Treatment of adult patients with Philadelphia chromosome or bcr/ abl translocation positive chronic myelogenous leukaemia.
Klinisk erfaring indikerer, at et hæmatologisk og cytogenetisk større/ mindre respons er opnåeligt hos størstedelen af behandlede patienter.
Clinical experience indicates that a haematological and cytogenetic major/ minor response is obtainable in the majority of patients treated.
2 leukæmiske celler i knoglemarven, mens et mindre respons er  34%, men < 90% Ph+ celler i marven.
A major cytogenetic response is defined by < 34% Ph+ leukaemic cells in the bone marrow, whereas a minor response is  34%, but < 90% Ph+ cells in the marrow.
Kombinationsbehandling:
 2 Combination therapy:
Kombinationen af interferon alfa- 2b og cytarabin (Ara- C) givet under de første 12 måneders behandling har vist signifikant at øge hyppigheden af større cytogenetisk respons og signifikant at forlænge den samlede overlevelse efter 3 år sammenlignet med interferon alfa- 2b givet alene.
The combination of interferon alfa-2b and cytarabine (Ara-C) administered during the first 12 months of treatment has been demonstrated to significantly increase the rate of major cytogenetic responses and to significantly prolong the overall survival at three years when compared to interferon alfa-2b monotherapy.
Myelomatose:
Multiple Myeloma:
Som vedligeholdelsesbehandling hos patienter, som har opnået objektiv remission (mere end 50% reduktion i myeloid protein) efter initial induktionskemoterapi.
As maintenance therapy in patients who have achieved objective remission (more than 50% reduction in myeloma protein) following initial induction chemotherapy.
Imidlertid er effekt på den samlede overlevelse ikke afgørende bevist.
Current clinical experience indicates that maintenance therapy with interferon alfa-2b prolongs the plateau phase; however, effects on overall survival have not been conclusively demonstrated.
Follikulært lymfom:
Follicular Lymphoma:
Behandling af follikulær lymfom med stor tumorbyrde i kombination med passende induktionskemoterapi, såsom CHOP- lignende regimer.
Treatment of high tumour burden follicular lymphoma as adjunct to appropriate combination induction chemotherapy such as a CHOP-like regimen.